Literature DB >> 6447526

Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes.

C W Francis, V J Marder, S E Martin.   

Abstract

Plasmic degradation of crosslinked fibrin has been studied to identify the proteolytic cleavages that convert the clot into a soluble lysate and also to identify the derivatives that are likely to circulate during clot dissolution. Initial polypeptide chain cleavages do not disrupt the solid clot matrix. With continued exposure to plasmin, high molecular weight derivatives are produced that remain attached to the clot by noncovalent forces. Further degradation then results in the liberation into solution of several large, noncovalently bound complexes. Progressive degradation of the largest, initially liberated complexes to the terminal derivatives, DD/E, DD, and E, occurs in solution after their release from the clot. As the fibrin clot is exposed to plasmin for longer intervals, progressive dissolution occurs, but the structure of the covalently bound insoluble fibrin core, the noncovalently attached derivatives, and the liberated complexes remains constant. Since much of the initially liberated protein is in complexes larger than DD/E, these derivatives probably represent the more prevalent plasmic degradation products of crosslinked fibrin in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447526

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Enhancement of fibrinolysis in vitro by ultrasound.

Authors:  C W Francis; P T Onundarson; E L Carstensen; A Blinc; R S Meltzer; K Schwarz; V J Marder
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin.

Authors:  M W Mosesson; K R Siebenlist; D L Amrani; J P DiOrio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Usefulness of a latex agglutination assay for FDP D-dimer to demonstrate the presence of postmortem blood.

Authors:  Koichi Sakurada; Ikuko Sakai; Kazumasa Sekiguchi; Tomoko Shiraishi; Hiroshi Ikegaya; Ken-ichi Yoshida
Journal:  Int J Legal Med       Date:  2005-01-15       Impact factor: 2.686

4.  Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII.

Authors:  C W Francis; V J Marder
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

5.  Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.

Authors:  C W Francis; V J Marder; G H Barlow
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

6.  Characterization of the inhibition of fibrin assembly by fibrinogen fragment D.

Authors:  J E Williams; R R Hantgan; J Hermans; J McDonagh
Journal:  Biochem J       Date:  1981-09-01       Impact factor: 3.857

7.  Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.

Authors:  J I Weitz; B Leslie; J Hirsh; P Klement
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.

Authors:  D J Pinsky; H Liao; C A Lawson; S F Yan; J Chen; P Carmeliet; D J Loskutoff; D M Stern
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.

Authors:  J I Weitz; B Leslie; J Ginsberg
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  PKCbeta regulates ischemia/reperfusion injury in the lung.

Authors:  Tomoyuki Fujita; Tomohiro Asai; Martin Andrassy; David M Stern; David J Pinsky; Yu Shan Zou; Morihito Okada; Yoshifumi Naka; Ann Marie Schmidt; Shi-Fang Yan
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.